On Thursday, Capstead Mortgage Corporation (NYSE:CMO)’s shares declined -2.63% to $11.12.
Capstead Mortgage Corporation (CMO) declared financial results for the quarter ended June 30, 2015.
Second Quarter 2015 Highlights
- Generated earnings of $24.9 million or $0.22 per diluted common share
- Paid common dividend of $0.31 per common share
- Book value reduced 1.4%, or $0.17 to $12.30 per common share
- Financing spreads on residential mortgage investments reduced 27 basis points to 0.84%
- Mortgage prepayments raised to an annualized constant prepayment rate, or CPR, of 21.98% from 16.66% CPR stated for the first quarter of 2015
- Agency-guaranteed ARM portfolio and leverage ended the quarter at $14.16 billion and 8.76 times long-term investment capital, respectively
Capstead Mortgage Corporation operates as a real estate investment trust (REIT) in the United States. It invests in a portfolio of residential mortgage pass-through securities comprising of adjustable-rate mortgage securities issued and guaranteed by government-sponsored enterprises or by an agency of the federal government.
Amgen, Inc. (NASDAQ:AMGN)’s shares gained 0.13% to $171.69.
Amgen (AMGN) declared positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled study evaluating the safety and efficacy of AMG 334 for the prevention of episodic migraine. Patients who entered the open-label phase received AMG 334 70 mg monthly and practiced a sustained reduction in monthly migraine days at week 52.
At one year, patients receiving AMG 334 70 mg practiced an average of a -4.9-day reduction from a baseline of 8.7 mean monthly migraine days, regardless of treatment received during the blinded phase. The 50 percent responder rate (greater than 50 percent reduction in monthly migraine days) was 62 percent at 52 weeks. Additional responder rates were stated for the first time: at 52 weeks the 75 percent responder rate was 38 percent and the 100 percent responder rate was 19 percent.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products comprise Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products comprise Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials.
At the end of Thursday’s trade, CVS Health Corp (NYSE:CVS)‘s shares dipped -0.45% to $112.94.
CVS Health Corporation (CVS) declared that its board of directors has approved a quarterly dividend of $0.35 (35 cents) per share on the corporation’s common stock. The dividend is payable on August 3, 2015, to holders of record on July 23, 2015.
CVS Health Corporation, together with its auxiliaries, provides integrated pharmacy health care services in the United States. The company operates through Pharmacy Services and Retail Pharmacy segments. The Pharmacy Services segment offers pharmacy benefit administration services, such as plan design and administration, formulary administration, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network administration services, prescription administration systems, clinical services, disease administration programs, and medical pharmacy administration services.
Air Products & Chemicals, Inc. (NYSE:APD), ended its Thursday’s trading session with 6.11% gain, and closed at $142.34.
Air Products ( APD ) stated net income of $359 million*, up 14 percent* as compared to preceding year, and diluted earnings per share (EPS) of $1.65*, up 13 percent* as compared to preceding year for its fiscal third quarter ended June 30, 2015.
On a GAAP basis, net income and diluted EPS from ongoing operations were $319 million and $1.47, respectively, for the quarter.
*The results and guidance in this release, unless otherwise indicated, are based on non-GAAP ongoing operations. A reconciliation of GAAP to non-GAAP results can be found at the end of this release.
Third quarter sales of $2,470 million reduced six percent as compared to preceding year, as underlying sales growth of four percent was offset by unfavorable currency and lower energy pass-through. Volumes raised three percent, primarily in Industrial GasesAsia, Materials Technologies and the LNG business, and pricing was up one percent.
Operating income of $482 million raised 17 percent as compared to preceding year, and operating margin of 19.5 percent improved 380 basis points, driven by cost performance, higher pricing and higher volumes. Adjusted EBITDA of $758 million raised nine percent over preceding year, and EBITDA margin of 30.7 percent improved 430 basis points, reflecting strong operating leverage.
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, performance materials, equipment, and services worldwide. The company operates in Merchant Gases, Tonnage Gases, Electronics and Performance Materials, and Equipment and Energy segments. The Merchant Gases segment sells atmospheric gases, such as oxygen, nitrogen, and argon; process gases, such as hydrogen, helium, and carbon dioxide; specialty gases; temporary gas supply services; and equipment for the metals, glass, electronics, chemical processing, food processing, healthcare, general manufacturing, and petroleum and natural gas industries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
